about
sameAs
A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisDrug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South AfricaCorrection: Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South AfricaProgrammatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South AfricaHigh frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosisMycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiologyWhole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolatesMicroevolution of the direct repeat region of Mycobacterium tuberculosis: implications for interpretation of spoligotyping data.Isolation and Potential for Transmission of Mycobacterium bovis at Human-livestock-wildlife Interface of the Serengeti Ecosystem, Northern TanzaniaThe non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South AfricaPopulation structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa.Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South AfricaPopulation structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent.Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.Genetic diversity of Mycobacterium tuberculosis isolated from tuberculosis patients in the Serengeti ecosystem in TanzaniaTreatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.Spoligotype signatures in the Mycobacterium tuberculosis complex.A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause diseaseNovel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages.Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa.Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa.Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalenceFluorometric assay for testing rifampin susceptibility of Mycobacterium tuberculosis complex.Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South AfricaThe diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates.Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa.Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosisEpistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis.Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape.Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.Clonal expansion of a globally disseminated lineage of Mycobacterium tuberculosis with low IS6110 copy numbers.Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic ValueLong-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.
P50
Q27011264-720520CF-C2E7-438B-997B-20001D68B956Q28487731-11ACDA7D-3907-4EF8-98E1-E87E85B22804Q28533564-EA2DE3BF-DD9E-4ED8-B330-C3B9BBBD58F3Q28535594-0C5787F9-1A27-4F84-A69F-A01980238188Q28546682-08B1D428-6DC8-40A9-BC66-7C0E595A2936Q29615131-9F95B0E5-BBEE-4079-9673-366FC5DD30E4Q30202327-C5D8526D-4FB1-4F30-B67F-CCA7B050CB54Q30749810-677B638A-87EC-43F1-8998-58BF3BAE7775Q33698244-E81A4EE6-E126-4EE2-830D-BC5AC4A75E08Q33756724-C94439D0-4BB2-4AAB-A063-6B7C3D5055EFQ34101580-04B3211C-0050-4DE0-B59C-92C0D3E9C322Q34216252-2CD2A6A4-6760-49A2-A2B9-307A5EA0D024Q34922107-84BB5C71-E074-4B0E-967A-5EF6B4E961A9Q35036087-A6D50C73-2DF9-4A36-A30E-DDE34843A751Q35191357-7F37D99B-C484-4907-991C-7EA3ABD7E125Q35452446-A066825B-B5B6-4714-AD5C-90A7C4F1C5D5Q35690253-6E763D2C-961A-490E-BC74-33A695B475BDQ35784560-3D630201-AB2C-4BF2-84A6-FF3042E3F880Q35909558-A3EAAEA2-F8CB-4392-B4FB-2535A6F4A84AQ35938811-6ADBDCA4-94E9-457F-A1D3-7CB52A1CC376Q36173979-AB6B0123-91E2-439D-AE83-EAA4D5686B56Q36174022-C7058835-D13B-48AB-BD89-D591B068B0E3Q36240511-A4760F3A-01EE-4BFD-8042-570D8D0CE0D0Q36539733-B34D9BB5-7460-44A5-B6C8-7AF67E8231DEQ36539796-33DB827B-76E8-4ECF-821E-159B18D67F71Q36555280-0600C248-B701-4A66-8B38-5E6A8AEAC9EBQ36564933-5E570CB6-BEC9-4F84-B862-F432FBFCD58DQ36825946-8DF332DA-F4B6-4401-8723-829A8878C47DQ37015588-91145A30-0AC5-46B0-BA2A-780254A72E02Q37133281-13C5D9B9-ED0F-4786-94E5-47659C29FB53Q37404250-DF1CD731-0C08-4F90-97C6-9E9A6193C08AQ37455406-373C9A7D-CFB7-4237-83CE-EA3F4FB19D07Q37460800-51D8A5BB-E5A9-428B-8BA7-7B87FF227779Q37702404-D8EAB606-0F23-4FE3-9B8E-7756D66A82CDQ37917035-76AFFE9C-3B10-4744-998B-34B6D5A771F2Q38410826-9EFDCC3D-62F8-45E1-BAA1-169ECB0EE6D6Q38971924-F1B7AA88-973D-4812-8790-617E542AA954Q38999525-8ADDCDAA-B330-4629-9F59-DCB35C5FD109Q39355934-01FD8477-79B8-43CF-A81A-2E5A6BC2009FQ40332311-FEC0905E-02B7-4978-84EF-954AC924C61F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elizabeth Streicher
@ast
Elizabeth Streicher
@en
Elizabeth Streicher
@es
Elizabeth Streicher
@nl
Elizabeth Streicher
@sl
type
label
Elizabeth Streicher
@ast
Elizabeth Streicher
@en
Elizabeth Streicher
@es
Elizabeth Streicher
@nl
Elizabeth Streicher
@sl
altLabel
Elizabeth M. Streicher
@en
prefLabel
Elizabeth Streicher
@ast
Elizabeth Streicher
@en
Elizabeth Streicher
@es
Elizabeth Streicher
@nl
Elizabeth Streicher
@sl
P106
P1153
7006160147
P21
P31
P496
0000-0003-3901-1981